Standard BioTools Inc. (LAB) Spending and interest coverage
- R&D / revenue · 12 months: Value 21.77%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 32.02%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 21.77% | Research and development expense / revenue. Period ending 2026-06-30. $18.42M ÷ $84.60M × 100 ≈ 21.77% |
| Stock-based compensation / revenue · 12 months | 32.02% | Share-based compensation / revenue. Period ending 2026-06-30. $27.09M ÷ $84.60M × 100 ≈ 32.02% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 18.42M USD | Research and Development Expense |
| Revenue | 84.60M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 27.09M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -95.47M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.42M | $84.60M | $27.09M | $-95.47M | (m) | 21.77% | 32.02% | (m) | (m) |
| 2026-03-31 | $22.66M | $86.25M | $29.43M | $-95.78M | (m) | 26.28% | 34.12% | (m) | (m) |
| 2025-12-31 | $25.99M | $85.33M | $29.61M | $-110.25M | (m) | 30.45% | 34.70% | (m) | (m) |
| 2025-09-30 | $58.64M | $169.74M | $31.34M | $-159.44M | (m) | 34.55% | 18.46% | (m) | (m) |
| 2025-06-30 | $59.22M | $172.27M | $28.79M | $-153.20M | (m) | 34.38% | 16.71% | (m) | (m) |
| 2025-03-31 | $57.76M | $169.69M | $29.13M | $-148.02M | (m) | 34.04% | 17.17% | (m) | (m) |
| 2024-12-31 | $62.41M | $174.43M | $31.73M | $-175.24M | (m) | 35.78% | 18.19% | (m) | (m) |
| 2024-09-30 | $55.27M | $155.90M | $27.74M | $-163.81M | (m) | 35.45% | 17.79% | (m) | (m) |
| 2024-06-30 | $48.54M | $136.30M | $25.20M | $-153.26M | (m) | 35.61% | 18.49% | (m) | (m) |
| 2024-03-31 | $35.50M | $126.76M | $21.59M | $-120.19M | (m) | 28.00% | 17.03% | (m) | (m) |
| 2023-12-31 | $25.95M | $106.34M | $13.12M | $-76.60M | $4.57M | 24.40% | 12.34% | -16.77× | Reported |
| 2023-09-30 | $27.58M | $105.17M | $11.33M | $-76.33M | $4.66M | 26.22% | 10.77% | -16.38× | Reported |
| 2023-06-30 | $29.70M | $105.45M | $12.44M | $-84.18M | $4.49M | 28.16% | 11.79% | -18.77× | Reported |
| 2023-03-31 | $36.04M | $96.56M | $13.99M | $-105.30M | $4.42M | 37.32% | 14.48% | -23.83× | Reported |
| 2022-12-31 | $38.50M | $97.95M | $14.88M | $-116.20M | $4.33M | 39.30% | 15.19% | -26.83× | Reported |
| 2022-09-30 | $38.66M | $109.19M | $17.56M | $-106.35M | $4.21M | 35.41% | 16.08% | -25.24× | Reported |
| 2022-06-30 | $39.22M | $112.05M | $17.39M | $-96.94M | $4.13M | 35.00% | 15.52% | -23.46× | Reported |
| 2022-03-31 | $36.06M | $124.29M | $16.47M | $-75.64M | $3.97M | 29.01% | 13.25% | -19.07× | Reported |
| 2021-12-31 | $37.94M | $130.58M | $16.10M | $-67.46M | $3.82M | 29.06% | 12.33% | -17.65× | Reported |
| 2021-09-30 | $40.59M | $136.92M | $15.83M | $-73.10M | $3.64M | 29.64% | 11.56% | -20.08× | Reported |
| 2021-06-30 | $39.51M | $148.28M | $15.87M | $-58.96M | $3.56M | 26.64% | 10.70% | -16.57× | Reported |
| 2021-03-31 | $38.52M | $143.32M | $15.76M | $-55.41M | $3.56M | 26.87% | 11.00% | -15.57× | Reported |
| 2020-12-31 | $36.46M | $138.14M | $14.45M | $-51.04M | $3.57M | 26.39% | 10.46% | -14.29× | Reported |
| 2020-09-30 | $33.55M | $125.98M | $13.46M | $-43.31M | $3.33M | 26.63% | 10.68% | -13.03× | Reported |
| 2020-06-30 | $32.55M | $112.61M | $12.13M | $-51.66M | $2.88M | 28.90% | 10.77% | -17.91× | Reported |
| 2020-03-31 | $31.97M | $114.75M | $11.49M | $-52.58M | $2.48M | 27.86% | 10.01% | -21.22× | Reported |
| 2019-12-31 | $31.64M | $117.24M | $11.39M | $-51.84M | $4.28M | 26.99% | 9.72% | -12.11× | Reported |
| 2019-09-30 | $31.32M | $117.13M | $13.26M | $-53.78M | $7.71M | 26.74% | 11.32% | -6.98× | Reported |
| 2019-06-30 | $31.63M | $119.59M | $12.53M | $-51.59M | $11.28M | 26.44% | 10.48% | -4.57× | Reported |
| 2019-03-31 | $31.15M | $117.83M | $11.55M | $-49.74M | $14.71M | 26.43% | 9.80% | -3.38× | Reported |
| 2018-12-31 | $30.03M | $112.96M | $11.02M | $-48.16M | $13.89M | 26.58% | 9.76% | -3.47× | Reported |
| 2018-09-30 | $29.23M | $108.38M | $8.05M | $-45.78M | $11.28M | 26.97% | 7.43% | -4.06× | Reported |
| 2018-06-30 | $29.48M | $104.17M | $8.07M | $-49.75M | $8.72M | 28.30% | 7.75% | -5.71× | Reported |
| 2018-03-31 | $29.56M | $101.65M | $8.39M | $-53.46M | $6.26M | 29.08% | 8.26% | -8.54× | Reported |
| 2017-12-31 | $30.83M | $101.94M | $9.09M | $-58.36M | $5.82M | 30.24% | 8.92% | -10.02× | Reported |
| 2017-09-30 | $32.44M | $99.28M | $9.92M | $-67.32M | $5.83M | 32.68% | 9.99% | -11.56× | Reported |
| 2017-06-30 | $34.01M | $96.72M | $11.19M | $-70.20M | $5.83M | 35.16% | 11.57% | -12.05× | Reported |
| 2017-03-31 | $36.53M | $100.98M | $12.59M | $-71.86M | $5.82M | 36.17% | 12.47% | -12.34× | Reported |
| 2016-12-31 | $38.41M | $104.45M | $13.86M | $-73.19M | $5.82M | 36.78% | 13.27% | -12.58× | Reported |
| 2016-09-30 | $39.38M | $110.08M | $15.01M | $-69.19M | $5.81M | 35.77% | 13.64% | -11.90× | Reported |
| 2016-06-30 | $39.57M | $116.54M | $15.57M | $-58.51M | $5.81M | 33.96% | 13.36% | -10.07× | Reported |
| 2016-03-31 | $39.69M | $116.99M | $16.48M | $-55.02M | $5.81M | 33.92% | 14.09% | -9.47× | Reported |
| 2015-12-31 | $39.26M | $114.71M | $16.83M | $-50.16M | $5.81M | 34.23% | 14.67% | -8.64× | Reported |
| 2015-09-30 | $41.24M | $117.48M | $18.51M | $-46.30M | $5.80M | 35.10% | 15.76% | -7.98× | Reported |
| 2015-06-30 | $44.48M | $118.47M | $20.39M | $-51.54M | $5.81M | 37.55% | 17.21% | -8.88× | Reported |
| 2015-03-31 | $45.77M | $117.46M | $21.63M | $-49.26M | $5.77M | 38.96% | 18.41% | -8.54× | Reported |
| 2014-12-31 | $43.42M | $116.46M | $20.94M | $-51.84M | $5.34M | 37.29% | 17.98% | -9.70× | Reported |
| 2014-09-30 | $37.46M | $103.85M | $17.04M | $-46.65M | $3.90M | 36.07% | 16.41% | -11.98× | Reported |
| 2014-06-30 | $29.78M | $92.50M | $12.76M | $-38.55M | $2.44M | 32.19% | 13.80% | -15.78× | Reported |
| 2014-03-31 | $23.40M | $82.37M | $8.56M | $-30.16M | $1.03M | 28.41% | 10.39% | -29.29× | Reported |
| 2013-12-31 | $19.95M | $71.18M | $6.44M | $-18.65M | $14.00K | 28.03% | 9.04% | -1332.36× | Reported |
| 2013-09-30 | $18.46M | $65.96M | $5.72M | $-17.50M | $25.00K | 27.99% | 8.67% | -700.08× | Reported |
| 2013-06-30 | $17.53M | $60.46M | $5.01M | $-16.46M | $131.00K | 29.00% | 8.28% | -125.64× | Reported |
| 2013-03-31 | $16.52M | $55.92M | $4.41M | $-16.86M | $331.00K | 29.54% | 7.88% | -50.92× | Reported |
| 2012-12-31 | $16.60M | $52.33M | $4.09M | $-18.07M | $628.00K | 31.72% | 7.81% | -28.78× | Reported |
| 2012-09-30 | $16.34M | $49.67M | $3.85M | $-17.56M | $1.01M | 32.89% | 7.76% | -17.45× | Reported |
| 2012-06-30 | $15.56M | $47.48M | $3.48M | $-17.70M | $1.34M | 32.77% | 7.34% | -13.23× | Reported |
| 2012-03-31 | $14.99M | $45.11M | $2.94M | $-19.97M | $1.65M | 33.24% | 6.53% | -12.12× | Reported |
| 2011-12-31 | $13.94M | $42.87M | $2.80M | $-18.57M | $3.10M | 32.51% | 6.53% | -5.99× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $13.01M | $33.56M | $1.59M | $-14.57M | $2.16M | 38.76% | 4.73% | -6.75× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $12.31M | $25.41M | $2.11M | $-18.04M | $2.88M | 48.46% | 8.31% | -6.27× | Reported |
| 2003-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |